| [1] |
赫捷, 陈万青. 2017中国肿瘤登记年报[M].北京:人民卫生出版社, 2018.
|
| [2] |
Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy [J]. Cell, 2017, 170(3): 548-563.
|
| [3] |
Tsoi H, Chu ESH, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice [J]. Gastroenterology, 2017, 152(6): 1419-1433.
|
| [4] |
Jin Y, Tang S, Li W, et al. Hemolytic E.coli promotes colonic tumorigenesis in females [J]. Cancer Res, 2016, 76(10): 2891-2900.
|
| [5] |
Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment [J]. Cell Host Microbe, 2013, 14(2): 207-215.
|
| [6] |
Kawano A, Ishikawa H, Mutoh M, et al. Higher enterococcus counts indicate a lower risk of colorectal adenomas: a prospective cohort study [J]. Oncotarget, 2018, 9(30): 21459-21467.
|
| [7] |
Huycke MM, Abrams V, Moore DR. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA [J]. Carcinogenesis, 2002, 23(3): 529-536.
|
| [8] |
Nakatsu G, Li X, Zhou H, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis [J]. Nat Commun, 2015, 6: 8727.
|
| [9] |
Al-Homoud S, Purkayastha S, Aziz O, et al. Evaluating operative risk in colorectal cancer surgery: ASA and POSSUM-based predictive models [J]. Surg Oncol, 2004, 13(2-3): 83-92.
|
| [10] |
陈文杰, 苏献豪, 王跃迁, 等. 姜黄素干预小鼠肠道菌群并抑制结直肠癌变的实验研究 [J/CD]. 中华结直肠疾病电子杂志, 2018, 7(6): 538-545.
|
| [11] |
Yan X, Liu L, Li H, et al. Clinical significance of Fusobacterium nucleatum, epithelial-mesenchymal transition, and cancer stem cell markers in stage Ⅲ/Ⅳ colorectal cancer patients [J]. Onco Targets Ther, 2017, 10: 5031-5046.
|
| [12] |
Balamurugan R, Rajendiran E, George S, et al. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer [J]. J Gastroenterol Hepatol, 2008, 23(8): 1298-1303.
|
| [13] |
De Almeida CV, Lulli M, di Pilato V, et al. Differential responses of colorectal cancer cell lines to enterococcus faecalis' strains isolated from healthy donors and colorectal cancer patients [J]. J Clin Med, 2019, 8(3): E388.
|
| [14] |
Wong SH, Kwong TNY, Chow TC, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia [J]. Gut, 2017, 66(8): 1441-1448.
|
| [15] |
Fu Y, Wang L, Xie C, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation [J]. Sci Rep, 2017, 7(1): 2669.
|
| [16] |
Todorov K, Wilson C, Sharplin G, et al. Faecal occult blood testing (FOBT)- based colorectal cancer screening trends and predictors of non-use: findings from the South Australian setting and implications for increasing FOBT uptake [J]. Aust Health Rev, 2018, 42(1): 45-52.
|